Molecular diagnostic solutions provider BioGX has announced that its Covid-19 tests hold the capacity to detect Omicron (B.1.1.529) SARS-CoV-2 variant.

The company’s SARS-CoV-2 surveillance programme consists of in-silico analysis and experimental testing by the firm’s scientists using RNA sequences that incorporate the mutations present within the emerging SARS-CoV-2 variants.

According to BioGX’s analysis, its Covid-19 test portfolio has detection coverage for all variants of interest and variants of concern, including the new Omicron variant.

The company’s portfolio includes Covid-19 RT-PCR tests for a range of real-time PCR platforms such as BD MAX system, Applied Biosystems 7500 Fast Dx, Applied Biosystems QuantStudio 5, Bio-Rad CFX96 Touch and Bio-Rad CFX384 Touch.

For high throughput applications, BioGX’s Xfree Covid-19 Direct RT-PCR test is said to be a preferred test due to its ease-of-use and flexibility.

To conduct the RT-PCR testing, an user has to rehydrate the lyophilised Xfree reagent with molecular grade water, add the patient sample and run the test on a validated real-time PCR instrument.

Xfree Covid-19 is claimed to be the only lyophilised, direct sample addition and extraction-free RT-PCR test to secure emergency use authorisation (FDA) from the US Food and Drug Administration (FDA) for different real-time PCR instruments and specimen types.

The test is also authorised to run with extracted samples, thereby enabling the laboratory to adapt the test for any of its workflow.

Based in Birmingham of Alabama and Dallas of Texas, BioGX offers lyophilised real-time PCR reagents for molecular diagnostics.

Through its global distribution network, the company markets more than 60 multiplex real-time PCR products across the world.